{"id":"NCT00136604","sponsor":"GlaxoSmithKline","briefTitle":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","officialTitle":"Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix-HepB/Hib-MenAC","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01-22","primaryCompletion":"2006-04-23","completion":"2006-04-23","firstPosted":"2005-08-29","resultsPosted":"2018-09-17","lastUpdate":"2020-02-20"},"enrollment":617,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Whole Cell Pertussis","Haemophilus Influenzae Type b","Hepatitis B","Diphtheria","Tetanus","Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin"],"interventions":[{"type":"BIOLOGICAL","name":"Tritanrix-HepB/Hib-MenAC","otherNames":[]},{"type":"BIOLOGICAL","name":"Mencevax ACWY","otherNames":[]},{"type":"BIOLOGICAL","name":"Tritanrix-HepB/Hiberix","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningitec","otherNames":[]}],"arms":[{"label":"ACAC GROUP","type":"EXPERIMENTAL"},{"label":"ACHibPS GROUP","type":"EXPERIMENTAL"},{"label":"HibACPS GROUP","type":"EXPERIMENTAL"},{"label":"HibHibPS GROUP","type":"EXPERIMENTAL"},{"label":"CC GROUP","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of DTPw-HBV/Hib-MenAC compared to DTPw-HBV/Hib given to healthy subjects at 15 to 24 months of age primed with 3 doses of Tritanrix-HepB/Hib-MenAC in study 100480. Antibody persistence will be evaluated at 24 to 30 months. Immunogenicity, safety and reactogenicity of a dose of Mencevax ACWY given at 24 to 30 months will also be evaluated when given to subjects not boosted with a MenA conjugate and/or MenC containing vaccine.","primaryOutcome":{"measure":"Percentage of Subjects With Meningococcal C Serum Bactericidal Assay (SBA-MenC) Antibody Titers Above the Cut-off Value","timeFrame":"One month Post-Booster vaccination at 15-24 months of age","effectByArm":[{"arm":"ACAC GROUP","deltaMin":100,"sd":null},{"arm":"CC GROUP","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"427 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":3,"countries":["Thailand"]},"refs":{"pmids":[],"seeAlso":["http://www.clinicaltrials.gov/ct/show/NCT00317161"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":249},"commonTop":["Pain","Irritability","Somnolence","Erythema","Pyrexia"]}}